Core Insights - IMUNON, Inc. is advancing its DNA-mediated immunotherapy, IMNN-001, which shows promising survival data for women with advanced ovarian cancer, with presentations scheduled at major oncology conferences [1][2][4] - The OVATION 2 Study demonstrated significant improvements in overall survival and progression-free survival for patients treated with IMNN-001 in combination with standard chemotherapy [2][5] - IMNN-001 utilizes a proprietary TheraPlas technology platform, delivering interleukin-12 (IL-12) to enhance anti-cancer immunity, marking it as the first IL-12 immunotherapy to show clinical efficacy in advanced ovarian cancer [3][7] Company Overview - IMUNON is a clinical-stage biotechnology company focused on innovative treatments that leverage the body's immune response, with a particular emphasis on non-viral DNA technology [9][10] - The company is developing multiple modalities, including TheraPlas for gene-based delivery of cytokines and PlaCCine for viral antigens, aiming to address solid tumors and other challenging conditions [9][10] Study Details - The Phase 2 OVATION 2 Study involved 112 patients with newly diagnosed advanced epithelial ovarian cancer, evaluating the safety and efficacy of IMNN-001 combined with neoadjuvant and adjuvant chemotherapy [5][6] - The study's design included a randomized approach comparing IMNN-001 plus standard chemotherapy against standard chemotherapy alone, focusing on overall survival as the primary endpoint [4][6] Future Directions - IMUNON is preparing for the pivotal Phase 3 OVATION 3 Study, which will further assess IMNN-001 in a larger cohort of women with advanced ovarian cancer, including those with specific genetic mutations [4][10] - The company anticipates regulatory review for IMNN-001 in the European Union and other global markets, aiming to improve treatment standards for advanced ovarian cancer [4][10]

Core Insights - Candel Therapeutics announced positive phase 3 clinical results for CAN-2409 in localized, intermediate-to-high risk prostate cancer, showing a statistically significant 30% reduction in disease recurrence compared to placebo when combined with standard-of-care radiation therapy [1][10] Company Overview - Candel Therapeutics is a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to combat cancer [11] - The company has established two clinical-stage platforms based on genetically modified adenovirus and HSV gene constructs, with CAN-2409 being the lead candidate from the adenovirus platform [11] Clinical Development - CAN-2409 (aglatimagene besadenovec) is designed to deliver the herpes simplex virus thymidine kinase (HSV-tk) gene to tumors, inducing a systemic immune response against cancer [8] - The investigational therapy has shown encouraging results in monotherapy and combination settings with standard treatments, with over 1,000 patients dosed and a favorable tolerability profile [9][10] - Candel is also evaluating CAN-2409 in non-small cell lung cancer (NSCLC) and borderline resectable pancreatic adenocarcinoma (PDAC) [10] Regulatory Status - CAN-2409 has received Fast Track Designation from the FDA for multiple indications, including PDAC and stage III/IV NSCLC, and has been granted Orphan Drug Designation for PDAC [10] Upcoming Events - Candel will host a webcast and conference call on June 3, 2025, to discuss the phase 3 clinical results and insights from leading prostate cancer specialists [1][5]

Core Viewpoint - Bridger Aerospace Group Holdings, Inc. has signed a Purchase and Sale Agreement for a sale leaseback transaction of its facilities at Bozeman Yellowstone International Airport for at least $46 million, aimed at reducing debt and ongoing cash interest [1][4]. Group 1: Transaction Details - The sale leaseback transaction is expected to close in the third quarter of 2025 and is subject to customary closing conditions [1]. - Concurrently, Bridger will enter into a ten-year lease agreement with SR Aviation Infrastructure for the hangar and office headquarters, allowing continued use for aerial firefighting operations [2]. Group 2: Company Background - Bridger Aerospace is one of the largest aerial firefighting companies in the U.S., providing services to federal and state agencies, including the U.S. Forest Service [5]. - The company is based in Belgrade, Montana, and focuses on wildfire management services both domestically and internationally [5]. Group 3: Strategic Implications - The CEO of Bridger expressed enthusiasm about the agreement, highlighting the opportunity to capitalize on real estate value and reduce the company's debt balance, which is expected to enhance shareholder value [4]. - The transaction reflects Bridger's commitment to the Bozeman area while enabling growth and operational efficiency [4].

Group 1 - Verizon's executive vice president and CEO for Verizon Consumer, Sowmyanarayan Sampath, will speak at the Bernstein Strategic Decisions Conference on May 29, 2025, at 8:00 a.m. ET, with a webcast available on the Investor Relations website [1] - Verizon generated revenues of $134.8 billion in 2024, highlighting its significant market presence and commitment to innovation [2] - The company serves millions of customers globally, including nearly all of the Fortune 500, focusing on mobility, reliable network connectivity, and security [2] Group 2 - Verizon's online media center provides access to news releases, stories, and media contacts, enhancing communication with stakeholders [3] - Media contacts for Verizon include Adi Wineland, who can be reached via email for inquiries [3]

- Study will assess relative efficacy, safety, and immunogenicity of Vaxart’s oral pill COVID-19 vaccine candidate against an approved mRNA comparator at 12 months - SOUTH SAN FRANCISCO, Calif., May 27, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced the first patient was dosed in the 10,000-participant portion of its ongoing Phase 2b clinical trial evaluating its oral pill COVID-19 vaccine candidate. “Initiating dosing in the 10,000-participant portion of this study is a significant st ...

NEWTOWN, Pa., May 27, 2025 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (NASDAQ: TRAW) (“Traws Pharma”, “Traws” or “the Company”), a clinical-stage biopharmaceutical company developing novel therapies to target critical threats to human health from respiratory viral diseases, today announced receipt of written responses to questions submitted for a Type B pre-Investigational New Drug Application meeting with the U.S. Food and Drug Administration (FDA, the Agency). The FDA provided feedback on development paths fo ...

- Safety and clinical outcomes of Phase 1 study of VCN-01 (zabilugene almadenorepvec) in refractory retinoblastoma patients to be presented in a poster session at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago on Saturday, May 31st, 2025 – - Theriva senior management to attend the ASCO conference and participate in an off-site investigator meeting to review the topline data from the VIRAGE Phase 2b clinical trial of VCN-01 in first-line metastatic pancreatic ductal adenocarcinoma ...

Core Insights - Super League has expanded its partnership with AdArcade to enhance revenue diversification through a patented mobile ad format that delivers three times higher engagement than standard playable ads [1][3] - The partnership allows Super League to provide brands and media agencies with a scalable, full-funnel playable solution, reaching 220 million monthly gamers in the US [1][3] Revenue Diversification Strategy - The expansion into mobile games is a key pillar of Super League's revenue diversification strategy, expected to account for 25% of the company's revenues in 2025 [3] - The company anticipates that the demographic of video game players will continue to grow, with projections indicating that three out of four individuals under 50 will play video games [3] Ad Performance Metrics - Native Playables, the interactive ads developed by AdArcade, achieve a return on ad spend (ROAS) as high as 13 times compared to standard playable ads [2][3] - The ads are designed to match the gameplay experience, leading to superior performance across key metrics [2][3] Audience Engagement - Native Playables target a broad audience, including Millennials, Gen X, Gen Z, and Gen Alpha, who engage with popular mobile games like Roblox, Minecraft, and Fortnite [4][7] - The partnership aims to effectively engage a multi-generational mobile gaming audience, enhancing brand visibility and consumer interaction [4][7] Operational Efficiency - The deployment of Native Playables can be completed in less than two weeks, with ad creation taking just hours due to AdArcade's automated system [3] - This efficiency allows brands to rapidly produce multiple playable ads tailored to specific demographic audiences [3]

SSCP Lager BidCo AB (publ) – Interim report for the period 1 January – 31 March 2025. Today SSCP Lager Bidco AB (publ) published an interim report for the first quarter, the report can be downloaded on www.logent.se or via the link below. For more information, please contact:Andrzej Kulik, CFO, telephone number: +46 738 15 67 00, andrzej.kulik@logent.se or Joel Engström, CEO, telephone number: +46 734 36 36 29, joel.engstrom@logent.se This press release was published on 27th May at CET 14:00 This informati ...

SharpLink continues its online performance-based marketing company serving the U.S. sports betting and global iGaming industries Upon the closing of the Private Placement, SharpLink will adopt an Ethereum Treasury Strategy Joseph Lubin, the Founder and CEO of Consensys and Co-Founder of Ethereum, will become Chairman of the Board of Directors of the Company effective upon the closing of the private placement MINNEAPOLIS, May 27, 2025 (GLOBE NEWSWIRE) -- SharpLink Gaming, Inc. (NASDAQ:SBET) (the "Company" or ...